Related Experiment Videos
Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors
1Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Insights
New HMG-CoA reductase inhibitors offer potent cholesterol lowering effects, significantly advancing cardiovascular disease treatment. These agents show promise in reducing coronary events by targeting elevated LDL-cholesterol levels.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Arteriosclerosis, especially coronary heart disease, is a primary global cause of death.
- Elevated LDL-cholesterol is a key modifiable risk factor for coronary events.
- Existing therapies include resins, fibrates, and niacin.
Purpose of the Study:
- To review the emerging class of HMG-CoA reductase inhibitors for treating hyperlipidemia.
- To highlight their role in managing cardiovascular disease risk.
Main Methods:
- Review of existing literature on HMG-CoA reductase inhibitors.
- Discussion of approved and investigational agents like lovastatin, simvastatin, pravastatin, and SRI-62-320.
Main Results:
- HMG-CoA reductase inhibitors are potent cholesterol-lowering agents.
- Lovastatin and simvastatin are approved, with pravastatin filed for registration.
- A synthetic compound (SRI-62-320) is under clinical investigation.
Conclusions:
- HMG-CoA reductase inhibitors represent a significant therapeutic advance for cardiovascular disease.
- Long-term safety and proven efficacy in reducing cardiovascular events are crucial for widespread adoption.
Abstract:
Arteriosclerosis, particularly coronary heart disease, is the leading cause of morbidity and mortality in many areas of the world. Elevated cholesterol, particularly LDL-cholesterol, has been shown to be one of the major modifiable factors in reducing coronary events. Standard hypolipidemic therapies include resin, fibrates and niacin. This review emphasizes a significant new therapeutic class of hypolipidemic agents, namely the HMG-CoA reductase inhibitors. These are potent cholesterol lowering agents. Lovastatin is the first agent of this class to receive clinical approval in the U.S.A. Simvastatin, an analog of lovastatin, is also approved in several countries. Both these agents are administered as lactones and hydrolyzed to the open acid forms. Another HMG-CoA reductase inhibitor pravastatin has recently been filed for registration in several countries. A fourth compound (SRI-62-320) which is currently in clinical investigation is a totally synthetic structure. If long-term safety remains good and clinical efficacy as demonstrated by reduction of cardiovascular events is proven, the HMG-CoA reductase class of agents will be a significant advance in the treatment of cardiovascular disease.